| NCT06842498 | A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NOT_YET_RECRUITING | PHASE2 | 2025-09-15 | 2028-03-31 | 2028-03-31 |
| NCT04621331 | Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD | WITHDRAWN | PHASE3 | 2022-05-23 | 2022-05-23 | 2022-05-23 |
| NCT05301517 | A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies | COMPLETED | PHASE3 | 2022-03-16 | 2023-04-21 | 2023-04-03 |
| NCT04632940 | Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD | TERMINATED | PHASE3 | 2021-03-03 | 2023-12-14 | 2023-06-12 |
| NCT04419558 | Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | TERMINATED | PHASE3 | 2020-09-30 | 2023-09-04 | 2023-09-04 |
| NCT04371666 | Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD) | TERMINATED | PHASE3 | 2020-08-10 | 2023-08-17 | 2023-02-13 |
| NCT04484857 | Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants | COMPLETED | PHASE3 | 2020-07-22 | 2021-09-17 | 2021-07-09 |
| NCT04432298 | Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease | TERMINATED | PHASE2 | 2020-06-20 | 2021-03-22 | 2021-03-22 |
| NCT04410198 | Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants | COMPLETED | PHASE3 | 2020-05-26 | 2021-10-11 | 2021-06-30 |
| NCT04076943 | Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia | COMPLETED | PHASE2 | 2019-08-20 | 2021-04-23 | 2021-03-26 |
| NCT03955146 | Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | TERMINATED | PHASE3 | 2019-06-18 | 2023-08-28 | 2023-03-20 |
| NCT04059913 | Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney Disease | COMPLETED | PHASE4 | 2019-06-11 | 2021-12-17 | 2021-11-19 |
| NCT03941093 | Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer | COMPLETED | PHASE3 | 2019-05-10 | 2024-06-11 | 2024-06-11 |
| NCT03303066 | Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS) | COMPLETED | PHASE2, PHASE3 | 2018-06-06 | 2023-02-08 | 2023-01-11 |
| NCT03263091 | Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden | TERMINATED | PHASE3 | 2018-01-29 | 2023-06-20 | 2023-03-09 |
| NCT02606136 | Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | TERMINATED | PHASE2 | 2016-01-04 | 2023-08-09 | 2020-05-07 |
| NCT02652819 | FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis | COMPLETED | PHASE3 | 2015-12 | 2017-06-13 | 2017-01-24 |
| NCT02652806 | FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease | COMPLETED | PHASE3 | 2015-12 | 2017-06-14 | 2017-01-24 |
| NCT02273726 | Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis | COMPLETED | PHASE3 | 2015-01-15 | 2018-09-19 | 2018-09-19 |
| NCT02210559 | A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer | COMPLETED | PHASE1, PHASE2 | 2014-07-31 | 2021-12-15 | 2021-12-15 |
| NCT02052310 | Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants | COMPLETED | PHASE3 | 2014-02-11 | 2018-09-21 | 2018-09-21 |
| NCT01890265 | Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF) | COMPLETED | PHASE2 | 2013-07-30 | 2017-11-16 | 2017-11-16 |
| NCT01750190 | A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis | COMPLETED | PHASE3 | 2012-11-05 | 2018-09-24 | 2018-09-24 |
| NCT01630889 | Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease | COMPLETED | PHASE2 | 2012-05-18 | 2019-12-12 | 2019-12-12 |
| NCT01599507 | Study of FG-4592 in Subjects With Chronic Kidney Disease in China | COMPLETED | PHASE2 | 2011-12 | 2013-01 | 2013-01 |
| NCT01596855 | Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China | COMPLETED | PHASE2 | 2011-09 | 2013-01 | 2013-01 |
| NCT01414075 | Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment | COMPLETED | PHASE2 | 2011-07-21 | 2013-01-10 | 2013-01-10 |
| NCT01262001 | Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis | COMPLETED | PHASE2 | 2011-03 | 2017-06-21 | 2014-06-26 |
| NCT01244763 | Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia | COMPLETED | PHASE2 | 2010-10-29 | 2012-06-13 | 2012-06-13 |
| NCT01217632 | A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection | TERMINATED | PHASE2 | 2010-08 | 2015-06 | 2015-06 |
| NCT01147666 | Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis | COMPLETED | PHASE2 | 2010-05-17 | 2012-10-15 | 2012-10-15 |
| NCT01376063 | Study to Investigate the Interaction Between FG-4592 and Rosiglitazone in Healthy Adult Subjects | COMPLETED | PHASE1 | 2010-03 | 2010-06 | 2010-05 |
| NCT00913393 | Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy | TERMINATED | PHASE2 | 2009-02 | 2010-06 | 2010-06 |
| NCT01181245 | A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer | COMPLETED | PHASE1 | 2008-12 | 2014-06 | 2014-05 |
| NCT00782561 | Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS) | TERMINATED | PHASE1 | 2008-04 | 2009-06-18 | 2009-06-18 |
| NCT00754143 | Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy | COMPLETED | PHASE1 | 2008-03 | 2009-12 | 2009-12 |
| NCT00761657 | Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis | COMPLETED | PHASE2 | 2006-11-01 | 2010-06-21 | 2010-06-21 |
| NCT00456053 | A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin | COMPLETED | PHASE2 | 2005-12 | 2007-07 | |
| NCT00102297 | Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus | COMPLETED | PHASE1 | 2005-01 | 2007-06 | |
| NCT00074698 | Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis | COMPLETED | PHASE1 | 2003-12-08 | 2004-05 | |